Nxera Pharma CoSOLTF 84 Piotroski F-Score is 4 as of Jun. 24, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates SOLTF with a GF Score™ of 84/100 and a GF Value™ of $7.77 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,341 Biotechnology companies, Nxera Pharma Co ranks better than 74.2% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Nxera Pharma Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Nxera Pharma Co's Piotroski F-Score or its related term are showing as below:
SOLTF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 5 Max: 8
Current: 4
During the past 13 years, the highest Piotroski F-Score of Nxera Pharma Co was 8. The lowest was 1. And the median was 5.
Nxera Pharma Co (OTCPK:SOLTF) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Nxera Pharma Co Piotroski F-Score Related Terms
Nxera Pharma Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Nxera Pharma Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOLTF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Nxera Pharma Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Nxera Pharma Co's current Net Income (TTM) was -82.1.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Nxera Pharma Co's return on assets of this year was -0.08396758. Nxera Pharma Co's return on assets of last year was -0.01415834.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Nxera Pharma Co's gearing of this year was 0.33232317. Nxera Pharma Co's gearing of last year was 0.3968856.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Nxera Pharma Co's current ratio of this year was 2.61243462. Nxera Pharma Co's current ratio of last year was 3.72125661.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Nxera Pharma Co's number of shares in issue this year was 89.941. Nxera Pharma Co's number of shares in issue last year was 89.941.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Nxera Pharma Co's gross margin of this year was 0.72290104. Nxera Pharma Co's gross margin of last year was 0.74081399.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Nxera Pharma Co's asset turnover of this year was 0.20037528. Nxera Pharma Co's asset turnover of last year was 0.20195218.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
1
+
0
+
0
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Nxera Pharma Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Nxera Pharma Co (SOLTF) has a Piotroski F-Score of 4 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Nxera Pharma Co and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Nxera Pharma Co's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Nxera Pharma Co ranks #346 out of 1341 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Nxera Pharma Co's Piotroski F-Score too high?
Nxera Pharma Co's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Nxera Pharma Co's value of 4 is 33.3% above this industry median. Based on the distribution chart, Nxera Pharma Co ranks #346 out of 1341 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nxera Pharma Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #346 out of 1341 companies for Piotroski F-Score. This puts Nxera Pharma Co in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Nxera Pharma Co's value of 4 is 33.3% above this benchmark. Historically, Nxera Pharma Co's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Nxera Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,341 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nxera Pharma Co's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Nxera Pharma Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nxera Pharma Co's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.77, compared to a current price of $6.37 — trading 18% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 33.3% above the Biotechnology industry median of 3.00. Nxera Pharma Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current Piotroski F-Score is 4 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (SOLTF) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued.
The current stock price of $6.37 is trading 18% below its estimated GF Value™ of $7.77.
GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.
Key valuation signals for SOLTF:
Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
GF Value™: $7.77 vs. price of $6.37 (18% below fair value)
Industry Position: 33.3% above the Biotechnology median (#346 of 1341)
No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
84GF Score
Get the complete analysis for SOLTF
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOLTF has been successfully added to your 
